Abstract
Background
The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial confirmed that percutaneous coronary intervention is no better than optimal medical therapy for the prevention of major adverse cardiac events in patients with stable angina. The impact of these findings on clinical practice remains unknown.
Hypothesis
Clinicians may more frequently opt for medical rather than procedural therapy of stable angina in response to the COURAGE trial.
Methods
Clinical information was collected from patients with stable angina referred to our hospital for cardiac catheterization between January 1, 2007 and June 18, 2007 (n = 332). Catheterization referral volume and the use of medications and coronary revascularization were compared before and after the release of the COURAGE trial.
Results
There was a significant increase in anti‐ischemia medication use prior to catheterization referral following the COURAGE trial (mean = 1.31 [SD 0.83] medications pre‐COURAGE, mean = 1.54 [SD 0.84] medications post‐COURAGE, P = 0.012). Among 217 patients with coronary disease on catheterization, treatment with medication rather than percutaneous or surgical revascularization increased after COURAGE (11.1% pre‐COURAGE vs 23.0% post‐COURAGE, P = 0.03). There was also a significant decrease in referral volume following the COURAGE trial (3.12 referrals/day pre‐COURAGE vs 2.51 referrals/day post‐COURAGE, P = 0.034).
Conclusions
The COURAGE trial immediately impacted the management of stable angina. Catheterization referral volume decreased, medication use increased, and the use of medical therapy rather than revascularization increased among patients with coronary disease. Copyright © 2009 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (84.1 KB).
References
- 1. Boden W, O'Rourke R, Teo K, et al. Optimal medical therapy with or without PCI for stable coronary disease. New Engl J Med 2007; 356(15): 1503–1516. [DOI] [PubMed] [Google Scholar]
- 2. Kereiakes D, Teirstein P, Sarembock I, et al. The truth and consequences of the COURAGE trial. J Am Coll Cardiol 2007; 50: 1598–1603. [DOI] [PubMed] [Google Scholar]
- 3. Diamond G, Kaul S. Courage under fire: On the management of stable coronary disease. J Am Coll Cardiol 2007; 50: 1604–1609. [DOI] [PubMed] [Google Scholar]
- 4. Sheikh F, Blumenthal R, Amsterdam E. The clinical outcomes utilizing revascularization and aggressive drug evaluation trial: a vindication of the power of medical therapy for the secondary prevention of coronary heart disease. Am J Card 2007; 100(12): 1808–1809. [DOI] [PubMed] [Google Scholar]
- 5. Winstein K. Stent implants declined in April; doctors attribute drop to study showing drugs may have similar benefits. The Wall Street Journal May 17, 2007; Sect. 3. [Google Scholar]
- 6. Berwick D. Disseminating innovations in health care. JAMA 2003; 289(15): 1969–1975. [DOI] [PubMed] [Google Scholar]
- 7. Stafford R. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000; 101: 1097–1101. [DOI] [PubMed] [Google Scholar]
- 8. Bruess J, Beasiri H, Mierzejewski R, et al. The state of health care quality, 2008. The National Committee for Quality Assurance 2008; Available at: http://www.ncqa.org. [Google Scholar]
- 9. Cannon C, Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia, PA: W.B. Saunders Company; 2001. [Google Scholar]